GenomeDx Biosciences, a genomic information company, announced Thursday that Tina Nova and Craig Johnson are joining its board of directors.
"Tina and Craig each have considerable leadership and expertise that will help launch GenomeDx into its next phase of growth," said Doug Dolgniow, CEO of GenomeDx.
Nova has been at the forefront of personalized cancer diagnostics for two decades. She co-founded the molecular diagnostics company Genoptix in 2000 and served as president, CEO and director until its acquisition by Novartis AG in 2011. Prior to that, Nova co-founded Nanogen Inc., a provider of diagnostic testing, where she served as president and COO.
Johnson has more than 25 years of experience leading companies and serving in senior financial management roles, primarily in the biotechnology industry. He is currently a director for Mirati Therapeutics, La Jolla Pharmaceutical Co. and Heron Therapeutics, and he also served as a director of Ardea Biosciences until its acquisition by AstraZeneca in 2012. He previously served as chief financial officer at NovaDel Pharma, TorreyPines Therapeutics and MitoKor.
Based in San Diego, GenomeDx Biosciences uses advanced cloud-based bioinformatics to mine vast amounts of genomic data. The company develops and commercializes proprietary clinical tests that provide actionable information to answer clinical questions in patient management.